Annual revenues from Lipitor reached over $12bn (€10.5bn) worldwide in the mid-2000s, but following its loss of exclusivity in November 2011 and the subsequent drop in sales, Pfizer announced it was selling the site in Cork, Ireland which makes the API for the anti-cholesterol drug.
But a U-turn earlier this year brought some relief to the 160 staff employed at Little Island and today’s announcement that Pfizer is adding jobs across its two plants in Cork should bring further reassurance.
Throughout 2015/2016 the Little Island and Ringaskiddy sites will be boosted by a total of 40 new jobs across a wide range of areas including Process Operators, Mechanical & Electrical/ Instrumentation Craft, Process Engineers, Process Chemists, and Quality Control Analysts.
“We are delighted to announce the news Pfizer is hiring,” said Seamus Fives, site Lead at the two plants.
“These are key roles within the organisation and play an important function in the manufacturing and delivery of medicines to patients worldwide.”
Applications are now open but if you are interested you better be quick, as Pfizer says the closing date is October 16.
Pfizer chose to retain the Little Island plant in March, after the firm saw an increase demand for its one-time blockbuster.
The facility is also manufacturing Pfizer’s newest small molecule cancer medicines, Spokesperson Karen O’Keefe told this publication today, and is benefitting from a $30m investment last year in a New Product Technology Laboratory (NPTL) at the Ringaskiddy plant – a site which also avoided closure following surprising post-expiration sales of erectile dysfunction drug Viagra